Based on breast CEUS parameters combined with

serum CA153, a nomogram model was constructed to 2

predict the molecular classification of breastcancer 3

- Yanlei Ji¹, Zhen Han², Yong Zhang³, Wenwen Sun^{1*}, 5
- ¹Department of Ultrasound Medicine, Shandong Cancer Hospital and Institute, 7
- Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan,
- 9 Shandong Province 250117, China
- ²Department of Internal Medicine, Jinan Second People's Hospital, Jinan, China. Jinan, 10
- Shandong Province 250022, China 11
- ³Department of Radiation Oncology, Shandong Cancer Hospital and Institute, 12
- Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 13
- 14 Shandong Province 250117, China
- *Corresponding author: Wenwen Sun 16
- telephone number: 18206413312 17
- E-mail: sunwenwen419@163.com 18
- Current Address: Shandong Cancer Hospital and Institute, Shandong First Medical 19
- University and Shandong Academy of Medical Sciences,440 Jiyan Road, Jinan, 20
- Shandong 21

4

6

15

22

23

24

25

26

27

Abstract

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

Objective: To analyze the role of contrast-enhanced ultrasound (CEUS) parameters combined with serum tumor marker CA153 in the prediction of Breast Cancer (BC) molecular typing. Methods: From January 2020 to January 2023, 120 BC patients diagnosed in our hospital were studied. According to the pathological results, the patients were divided into Luminal and non-Luminal BC groups. Both groups underwent contrast-enhanced ultrasoun. The time-intensity curve (TIC) is obtained, and the relevant characteristic parameters are obtained, including peak intensity (PI), peak time (TTP), area under the curve (AUC), and mean transit time (MTT). Serum tumor marker CA153 was detected in both groups. Combined with CEUS characteristic parameters and serum CA153 of two groups of BC patients, a multiple Logistic regression model was constructed, and a nomogram prediction model was constructed based on the model. Calibration curve and receiver operating characteristic (ROC) curve were used to analyze the value of this model in the prediction of BC molecular classification. Results: There were no significant differences between Luminal BC patients and non-Luminal BC patients in clinical parameters and qualitative parameters of contrast-enhanced ultrasound, while there were statistical differences between quantitative parameters PI, AUC and serum tumor marker CA153. The AUC of the combined diagnosis of three parameters (PI, AUC and CA153) was significantly higher than that of the single index diagnosis group. The ROC curve AUC of BC molecular typing was predicted to be 0.94 based on the threeparameter nomogram, and the fitting of the actual curve and the ideal curve in the

calibration curve was close. Conclusions: The nomogram model based on breast

contrast-enhanced ultrasound (CEUS) parameters combined with serum CA153 can

effectively predict the molecular classification of BC.

Keyword: Breast Cancer, CEUS, ROC, CA153

Introduction

52

53

54

55

56

Breast Cancer (BC) is one of the most common malignant tumors in wom 57 en. In recent years, its incidence has been increasing year by year and showing 58 a trend of youth, and seriously threatening the life health and quality of life of 59 patients^[1]. BC is a hormone-dependent tumor, and its carcinogenic risk is close 60 ly related to estrogen imbalance^[2-4]. Estrogen is mediated by estrogen receptor 61 (ER) and progesterone receptor (PR) and its expression level is different in dif 62 ferent BC patients, and its clinical manifestations, treatment and prognosis are 63 also different^[5, 6]. Based on the expression status of ER and PR, BC is divided 64 into Luminal type (positive for either ER or PR, including Luminal A and Lu 65 minal B) and non-Luminal type (negative for both ER and PR, including HER 66 -2 and TN)^[7]. Therefore, the development of accurate diagnostic methods for B 67 C patients with different molecular subtypes is very important for the treatment 68 and prognosis of patients^[8]. In recent years, with the development of molecular 69 biology technology, more tumor molecular markers related to BC have been di 70 scovered. Evaluating the expression levels of these markers in the serum of pat 71 ients can provide valuable information for the occurrence, invasion and metasta 72

sis of BC^[9]. Studies have suggested that carbohydrate antigen 153 (CA1563), c arcinoembryonic antigen (CEA) and carbohydrate antigen 125 (CA125) have ce rtain clinical value for BC screening, postoperative follow-up, recurrence and m etastasis, especially CA153, which is the most valuable single diagnostic index with the best sensitivity, accuracy, positive predictive value and specificity^[10]. However, CA153 alone cannot accurately reflect the overall situation of the les ion. contrast-enhanced ultrasound (CEUS), as a non-invasive imaging technique, can observe the microcirculation in BC lesions. At the same time, it can fully reflect the information of the internal and peripheral tissue structure of the lesi on^[11]. Based on this, the present study constructed a nomogram diagram with CEUS parameters combined with serum tumor marker index CA153 to predict different BC molecular typing, with a view to providing clinical reference for precise diagnosis and personalized treatment of BC.

Materials and methods

1.1 Patients

01/09/2024 searched the HIS information of our hospital, and selected 120 breast cancer patients diagnosed by examination from January 2020 ~ January 2023 as the research subjects. All patients underwent ultrasonography and clinical immunohistochemical pathology. Inclusion criteria: Invasive BC was confirmed by needle biopsy and immunohistochemical evaluation was performed; No chronic diabetes mellitus;

Patients volunteered to participate in the study; Complete medical records. Exclusion criteria: serious cardiovascular and cerebrovascular diseases and digestive tract diseases; Hypertension and autoimmune disease; Pregnancy or breastfeeding; Allergic to ultrasound contrast agent. This study was approved by the Ethics Committee of our hospital, and all patients have signed informed consent.

1.2 Contrast-enhanced ultrasound

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

GE Logiq E9 color Doppler ultrasonic diagnostic instrument, ML6-15 probe, frequency 9~15 MHz; Equipped with contrast-enhanced ultrasound imaging software. First, routine ultrasound was performed to observe the conditions of both mammary glands and determine the location of breast lesions to obtain better two-dimensional images. The optimal section was selected to cut into the angiography state, and 2.4 ml Sonovi (Bracco, Italy) was injected rapidly through the cubitus vein, and then rinsed with 5.0 ml 0.9% normal saline. The dynamic perfusion process of breast lesions was observed and recorded. The region of interest (diameter 4 mm, area 8 mm²) was selected when the breast lesions reached the peak of enhancement, and 5 points were selected from the inside and the edge of the lesions as the region of interest. The measured values of the region of interest at a total of 10 points were recorded and their mean values were taken. Start the QLAB analysis software to automatically analyze and obtain the timeintensity curve (TIC), and perform curve fitting to obtain the blood flow parameters of the region of interest: peak intensity (PI), peak time (TTP), area under the curve (AUC) and mean transit time (MTT). The above images were analyzed by two physicians. If there were any differences in the diagnosis results, the third physician would participate

in the discussion and get the final result after reaching an agreement.

1.3 Immunohistochemical examination

The expression levels of ER, PR, HER-2 and Ki-67 were detected in all BC samples after paraffin embedding and SP staining. ER, PR Rubric^[12]: ER and PR positive tumor nuclei ≥1% positive, < 1% negative. HER-2 Rubric^[13]: Negative 1+ is HER-2 negative and 3+ is HER-2 positive; those with 2+ need to be tested by fluorescence in situ hybridization, in which those with gene amplification are HER-2 positive and those without amplification are HER-2 negative. Ki-67 proliferation index^[12]: Select the area with the highest staining density of tumor cells, and count the staining of 1000 cells. The number of positive cells/total cell count is the Ki-67 proliferation index.

1.4 CA153 detection and judgment criteria

2 mL of fasting venous blood was collected from both groups of patients in the early morning, and then centrifuged at 3000 r/min for 10 min after self-coagulation to separate the serum, which was stored in the refrigerator at -20°C for examination. Serum CA153 concentration was detected by using Abbott Architecti 2000 automatic chemiluminescence immunoassay analyzer and special reagents. All operations were performed in strict accordance with the instrument and reagent instructions. The critical value of CA153 was 31.3 U/mL, and the assay was considered positive if the value exceeded the critical value.

1.5 Data analysis

All analyses were performed using R software version 4.0.2. Logistic regression and ROC analysis using R software. Measurement information data were expressed as Mean±SD and one-way ANOVA was used for comparison between groups. Count data data were expressed as frequencies and χ^2 test was used. Receiver operating characteristic curves (ROC) were used to analyze the diagnostic performance of the model for different BC subtypes. P<0.05 was statistically significant.

Results

2.1 Clinical characteristics

The 120 study patients ranged in age from 24 to 80 years. There were 72 patients with Luminal BC and 48 patients with non-Luminal BC. The general data of the study patients included age, maximum mass diameter, menopause, pathological type, and pathological grade, and the results were shown in Table 1. There was no significant difference in the general data of 120 patients with different BC types.

Table 1 Clinical characteristics

	A	Maximum		nopa	Dotho		Histological			
Molecula	Age	diameter	u	se	Pathological type				grade	
r type	(years, mea	(mm, mean	N	Ye	invasive ductal	invasive lobular	els	I,		
	n±SD)	±SD)	o	S	carcinoma	carcinoma	e	П	Ш	

perpetuity.

It is made available under a CC-BY 4.0 International license.

Luminal	52.68±10.0	22.57±9.56	55	17	48		12	12	45	18
	1									
Non-Lum	52.0±10.15	24.30±7.76	32	16	41		2	5	31	10
inal										
x^2/t	0.3626	1.044	1	365		0.1950			0.05	59
P	0.7175	0.2985	0	243		0.9071			0.80	08

2.2 CEUS manifestations

The results of comparing the qualitative parameters of ultrasonography in patients with different BC subtypes are shown in Figure 1 and Table 2. In patients with the Luminal type, ultrasonography is dominated by centripetal hyperenhancement, with a predominantly rapid ascending and slow descending enhancement pattern, and unclear and enlarged enhancement with radiolucent convergence of the borders; Centripetal enhancement accounted for 14/39 patients with the non-Luminal type, with a predominantly rapid ascending and slow descending pattern of enhancement, unclear and enlarged borders after enhancement, and radiolucent convergence of the borders.

Figure 1 Contrast-enhanced ultrasound of different molecular types of BC

(A: Ultrasonography of a patient with Luminal B BC showing radial convergence around the periphery of the mass on ultrasonography; B: Ultrasonography of a patient with TN BC showing a well-defined and well-formed lesion on ultrasonography)

Table 2 Contrast-enhanced ultrasound findings of patients with different BC types

Mole	Enhanced			Enhancement sequence			enhancement mode			d	ance -bou	Rad	ver	Enhand d rang		Per on defe	
cular type	Equ	lo	hi	offc	ent	dispe	slow g	_	Rapid growth	cle	unc	Ye	N	Eq	enl	Y	N
	al	W	gh	ente r	ad	rsion	slow d	slow d	slow d	ar	lear	S	O	ual	arg e	es	0
Lumi nal	18	1 5	39	17	32	23	12	56	4	14	58	49	2	19	53	44	2 8
Non- Lumi nal	8	1	39	7	14	27	8	36	4	22	26	28	2	27	21	30	1 8
x^2	12.16	07		11.92	45		4.8137			10.4	762	13.0)31	14.6	953	5.37	785
P	0.058			0.063			0.5679			0.06	549	0.05	54	0.06	2	0.14	460

2.3 Comparison of CEUS characteristic parameter and 172

CA153 173

171

The CEUS quantitative parameters and serum CA153 indexes of patients 174 with different BC types were compared, The results are shown in Table 3. Th 175

ere were significant differences in PI, AUC and serum CA153 between Lumina l and non-Luminal BC patients.

Table 3 Comparison of CEUS characteristic parameter and CA153

Molecular	PI(%)	TP(s)	AUC(%s)	MTT(s)	CA153(U/mL)	
type	11(70)	11 (8)	AUC(708)	WITT(S)	CA133(U/IIIL)	
Luminal	37.50±2.2	23.18±2.2	1576.11±272.	31.42±4.6	111 10 : 42 07	
Luminai	5	9	91	1	111.18±43.86	
Non-Lumina	44.53±7.1	23.55±4.2	1907.74±340.	32.42±5.2	94.57+20.20	
1	4	8	11	0	84.57±39.30	
t	6.600	0.541	5.961	1.112	3.401	
P	< 0.001	0.589	< 0.001	0.269	< 0.001	

2.4 Binary logistic regression analysis screened the independent predictors of BC molecular typing

To further evaluate the predictive performance of serum tumor marker CA153 and contrast-enhanced ultrasound parameters in different types of BC. Univariate regression analysis was performed to compare the clinical data, CEUS quantitative parameters and serum tumor marker CA153 between Luminal and non-Luminal subtypes. Subsequently, univariate factors with P values < 0.05 were included in the multivariate regression analysis, including CEUS parameters PI, AUC and serum tumor

marker CA153. Multivariate logistic regression analysis showed that PI, AUC and CA153 were independent predictors of BC molecular typing (P < 0.05).(Table 4).

Table 4 Binary logistic regression analysis screened the independent predictors of

BC molecular typing

189

190

191

Variate	Univariate re	egression ar	Multivariate regression analysis				
	OR	95%CI	P	OR	95%CI	P	
Ago	0.00	0.96,1.0	0.715				
Age	0.99	3	0.713	-	-	-	
Menopause	1.47	0.65,3.3	0.355				
Wenopause	1.47	3	0.333	-	-	-	
Maximum diamete	1.02	0.98,1.0	0.297	_	_	_	
r	1.02	7	0.271	_	-		
Histological grade	0.79	0.33,1.9	0.597	-	-	_	
Thistorogical grade		0					
Enhanced intensity	2.25	0.88,5.7	0.092		_	_	
=======================================	_,	8	0.032				
Enhancement sequ	2.73	0.97,7.7	0.058	_	_	_	
ence	2.73	1	0.000				
enhancement mode	1.50	0.29,7.8	0.630	_	_	_	
	1.50	1	0.030				

Enhanced post-bou	0.29	0.13,0.6	0.103			
ndary	0.2)	4	0.103	_	-	-
Radial convergenc	1.52	0.71,3.2	0.278	_		
e	1.52	5	0.276	_	_	
Enhanced range	0.58	0.13,0.6	0.215	_		
Emianeed range	0.50	0	0.213	_	_	
Perfusion defect	0.99	0.96,1.0	0.087		_	
retrusion defect	0.77	3				
PI	1.36	1.20,1.5	0.001	1.31	1.09,1.5	0.00
11		3			8	4
TP	1.04	0.92,1.1	0.542	_	_	_
	1.01	6	0.5 12			
AUC	1.01	1.01,1.0	<	1.01	1.01,1.0	0.00
7100	1.01	1	0.001	1.01	1	2
MTT	1.04	0.97,1.1	0.269	_	_	_
1411 1	1.04	3	0.20)			
CA153	0.98	0.98,0.9	0.002	0.98	0.96,0.9	0.00
C/1133	0.70	9	0.002	0.70	9	1

2.5 Construction of nomogram prediction model and comparative analysis of prediction efficiency

193

194

Based on the independent predictors (PI, AUC, CA153) of the three molecular subtypes of BC screened by binary logistic regression analysis, ROC curve was established to evaluate the accuracy of the combination of the three parameters in predicting non-Luminal BC (Figure 1). The results showed that the area under the curve (AUC) of the three-parameter model was 0.8307 (95%CI: 0.7437-0.9177), the sensitivity and specificity of the prediction were 75% and 94.44%, respectively, and the cut-off value of the prediction model was 0.3437. This indicates that the threeparameter combined prediction model of PI, AUC and serum CA153 has good predictive performance for the diagnosis of non-Luminal events (Table 5). Finally, we constructed a nomogram to predict the probability of non-Laminal BC based on the PI, AUC, and CA153 mentioned above (Figure 2). Each independent variable value corresponds to a score in the top row, and the scores of the individual independent variables are summed to obtain the total score, from which the probability is subsequently calculated. Finally, we used ROC curve and calibration curve to evaluate the predictive performance of the nomogram (Figure 3,4). The AUC of ROC curve was 0.94 (95%CI: 0.90-0.98). In the calibration curve, the actual curve was very close to the ideal curve. The nomogram has good predictive value for predicting the risk of non-Luminal BC.

Figure 2 ROC curve was predicted by three-parameter combination

Table 5 Comparison of AUC values

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

	AUC	95%CI
PI	0.8098	0.7163-0.9032
AUC	0.7590	0.6701-0.8478
CA153	0.6780	0.5799-0.7760
Combined	0.8307	0.7437-0.9177

Figure 3 ROC curve of the nomogram model

Figure 4 Calibration curve of nomogram model

Discussion

BC is a highly vascular heterogeneous and malignant stromal tumor, and i ts incidence is increasing year by year, which has become the first disease seri ously endangering women's health^[14]. The etiology of the disease is still unclea r, and genetic factors and estrogen endocrine abnormalities are the main causes of the disease^[15]. In 2000, Perou et al^[16] first proposed that BC has different molecular subtypes, which can be divided into Luminal type and non-Luminal type (including HER-2 type and TN type). Studies have found that different m olecular subtypes of BC have different biological behaviors, chemotherapy sensi tivity and prognosis. Among them, Luminal BC is the most common molecular subtype, accounting for about 50%-70% of BC including Luminal A and Lumi nal B subtypes. Non-Luminal BC includess two different subtypes, HER-2 and TN subtypes, and this molecular subtype of BC is highly heterogeneous and c haracterized by high invasiveness. Compared with Luminal BC, it is more diffi

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

cult to diagnose and treat. Therefore, early detection, early diagnosis and early treatment of different molecular subtypes of BC are of great significance for i mproving the survival rate and quality of life of patients. The occurrence, development, invasion and metastasis of BC are dependent on neovascular vessels. The marginal zone of tumor is an area with vigorous growth of tumor cells. The blood vessels are dense and densely distributed, an astomosing with each other to form loops, and some blood vessels are dilated in sinus shape^[17]. CEUS, as a non-invasive imaging method for preoperative ev aluation of tumor angiogenesis, can accurately display blood perfusion compared with conventional ultrasound. The application of contrast-enhanced ultrasound c an not only clearly observe the course and distribution of microvessels in the t umor, but also provide quantitative analysis of the tumor, providing imaging re ference for the preoperative diagnosis and treatment of BC^[18]. In this study, we compared the characteristics of contrast-enhanced ultrasound between the two gr oups of patients. We found that the contrast-enhanced ultrasound of Luminal B C showed high enhancement, unclear boundary, radial convergence around the periphery, and expanded range after enhancement, and the enhancement pattern was mostly rapid increase and slow decrease. This result is the same as that o f Wang Xiaoyan et al^[19], and can be used as a sensitive sign of Luminal BC. Non-Luminal BC showed high enhancement on contrast-enhanced ultrasound, an d the boundary was basically unclear after enhancement, and the boundary did

not significantly expand after enhancement, similar to the imaging characteristic

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

s of benign tumors, which was rare in other molecular subtypes, highlighting t he heterogeneity of this subtype. Whether the quantitative parameters of contras t-enhanced ultrasound are correlated with the molecular subtypes of BC, many studies have conflicting conclusions^[20]. Lin Yun^[21] believes that there is a cert ain correlation between the quantitative parameters of contrast-enhanced ultrasou nd in different molecular types of BC, and Jia Wanru^[22] believes that there is no statistically significant difference in the quantitative parameters of contrast-e nhanced ultrasound between different molecular types of BC. In this study, we found that there were significant differences in PI and AUC of contrast-enhanc ed ultrasound in patients with different BC subtypes, which may have guiding significance for predicting different molecular types of BC. At present, with the rapid development of genomics and molecular biology, different molecular subtypes of BC can better reflect the biological behavior of tumors. The detection of serum tumor markers can not only assist in diagnosis, but also effectively predict the efficacy, outcome and acquired drug resistance. CA153 is an antigen closely related to human breast malignant tumors. It was first found in BC epithelial cells as a variant of the epithelial surface glycopro tein of breast cells. When a cell undergoes cancerous transformation, the activa tion of glycosyltransferases causes changes in cell surface sugars and enters the blood with the tumor cells^[23]. It has obvious tumor specificity for BC and is of great significance for the early diagnosis of BC. The level of its serum content can be used as an index for the evaluation of the efficacy of BC^[24, 25], it is c

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

urrently clinically recognized as a more specific tumor marker for the diagnosis of BC. In this study, we found that the serum CA153 level was significantly higher in Luminal subtype patients than in non-Luminal subtype patients. There fore, we hypothesized that the serum CA153 difference in different BC subtype s combined with CEUS related parameters could help us to better predict the molecular subtype of BC. Based on this, we used multivariate Logistic regressi on to analyze the clinical data, contrast-enhanced ultrasound characteristic para meters and serum CA153 of the two groups of patients. The results showed th at the quantitative parameters of contrast-enhanced ultrasound PI, AUC and ser um CA153 were independent predictors of BC molecular typing. The ROC cur ve was used to compare the efficacy of PI, AUC, CA153 single parameters an d the combination of three parameters in the diagnosis of BC molecular typing, and the results showed that the AUC of the combination of three parameters was significantly higher than that of each parameter. Then we constructed a no mogram prediction model using three parameters, and evaluated the predictive performance of the model using ROC curve and calibration curve. The results of ROC curve and calibration curve showed that the nomogram had good pred ictive value for the risk of non-Luminal BC. In conclusion, the ultrasonographic features of BC can reflect the biologica 1 characteristics of different BC molecular typing and are closely associated wit h the serum tumor marker CA153. In this study, the ultrasonographic paramete rs of PI, AUC and serum CA153 were used to construct a columnar graphical

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

model to effectively predict the molecular typing of BC, which can provide ce rtain clinical references for accurate diagnosis and personalized treatment of BC. However, this study is a single-center retrospective analysis with a limited sam ple size, which did not explore the specific molecular typing of BC and lacked external data validation, so it needs to be further improved. **Author contributions** Yanlei Ji, Zhen Han, and Yong Zhang: study design, data analysis and int erpretation, and manuscript revision. Wenwen Sun: manuscript drafing. All the authors of this study read and approved the fnal manuscript. **Funding** No funding was granted for this study. **Competing interests** Authors declare no competing interests.

perpetuity.

It is made available under a CC-BY 4.0 International license.

References

- 338 [1] Zhi B, Yu J Q, Lv S Q. To establish a multi-parameter model to predict early triple-negativ 339 e breast cancer (TNBC)[J]. Radiologic Practice, 2021,36(8):1021-1025.DOI: 10.13609/j.cnki.1 340 000-0313.2021.08.014
- 341 [2] Burstein H J. Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cance 342 r[J]. N Engl J Med, 2020,383(26):2557-2570.DOI: 10.1056/NEJMra1307118
- [3] Clusan L, Le Goff P, Flouriot G, et al. A Closer Look at Estrogen Receptor Mutations in Br east Cancer and Their Implications for Estrogen and Antiestrogen Responses[J]. Int J Mol Sci, 2021,22(2).DOI: 10.3390/ijms22020756
- [4] Valko-Rokytovska M, Ocenas P, Salayova A, et al. Breast Cancer: Targeting of Steroid Hor
 mones in Cancerogenesis and Diagnostics[J]. Int J Mol Sci, 2021,22(11).DOI: 10.3390/ijms22
 115878
- [5] Farcas A M, Nagarajan S, Cosulich S, et al. Genome-Wide Estrogen Receptor Activity in Br east Cancer[J]. Endocrinology, 2021,162(2).DOI: 10.1210/endocr/bqaa224
- [6] Derakhshan F, Reis-Filho J S. Pathogenesis of Triple-Negative Breast Cancer[J]. Annu Rev P
 athol, 2022,17:181-204.DOI: 10.1146/annurev-pathol-042420-093238
- [7] Rella R, Belli P, Giuliani M, et al. Automated Breast Ultrasonography (ABUS) in the Screen
 ing and Diagnostic Setting: Indications and Practical Use[J]. Acad Radiol, 2018,25(11):1457-1
 470.DOI: 10.1016/j.acra.2018.02.014
- Subramanian S, Keating N L. Delays in breast cancer diagnosis after a state policy limiting Medicaid enrollment[J]. Cancer, 2017,123(17):3219-3221.DOI: 10.1002/cncr.30769
- 358 [9] Bidard F C, Hajage D, Bachelot T, et al. Assessment of circulating tumor cells and serum m 359 arkers for progression-free survival prediction in metastatic breast cancer: a prospective obser 360 vational study[J]. Breast Cancer Res, 2012,14(1):R29.DOI: 10.1186/bcr3114
- [10] Li X, Xu Y, Zhang L. Serum CA153 as biomarker for cancer and noncancer diseases[J]. Pro
 g Mol Biol Transl Sci, 2019,162:265-276.DOI: 10.1016/bs.pmbts.2019.01.005
- 363 [11] Ji C L, Li X L, He Y P, et al. Quantitative parameters of contrast-enhanced ultrasound in br 364 east invasive ductal carcinoma: The correlation with pathological prognostic factors[J]. Clin H 365 emorheol Microcirc, 2017,66(4):333-345.DOI: 10.3233/CH-170251
- 366 [12] National Health Commission Of The, S Republic Of China. Breast Cancer Guidelines (2022 edition)[J]. China Licensed Pharmacist, 2022,19(10):1-26
- 368 [13] Liu Y P, Bu H, Yang W T. Chinese breast cancer HER2 detection guidelines update inter 369 pretatio (2019 edition)[J]. Chinese Journal of Pathology, 2019,48(3):182-185.DOI: 10.3760/c 370 ma.j.issn.0529-5807.2019.03.004
- 371 [14] Sung H, Ferlay J, Siegel R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates o 372 f Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 373 2021,71(3):209-249.DOI: 10.3322/caac.21660
- 374 [15] Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mo 375 rtality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer, 2019,144(8):1941-1953. 376 DOI: 10.1002/ijc.31937
- 377 [16] Perou C M, Sorlie T, Eisen M B, et al. Molecular portraits of human breast tumours[J]. Natu re, 2000,406(6797):747-752.DOI: 10.1038/35021093

perpetuity.

It is made available under a CC-BY 4.0 International license .

- 379 [17] Bian X W, Jiang X F, Chen J H, et al. Increased angiogenic capabilities of endothelial cells 380 from microvessels of malignant human gliomas[J]. Int Immunopharmacol, 2006,6(1):90-99.DO 381 I: 10.1016/j.intimp.2005.08.004
- [18] Claudon M, Dietrich C F, Choi B I, et al. Guidelines and good clinical practice recommendat ions for contrast enhanced ultrasound (CEUS) in the liver--update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS [J]. Ultraschall Med, 2013,34(1):11-29.DOI: 10.1055/s-0032-1325499
- 386 [19] Wang X Y, Kang L K, Lan C Y et al. Characteristics and diagnosis of breast malignant ma 387 sses by contrast-enhanced ultrasound[J]. Chinese Journal of Ultrasonography, 2012,28(08):705 388 -708
- [20] He J. The application value of contrast-enhanced ultrasound in the diagnosis of breast tumors [J]. Journal of Clinical Ultrasound in Medicine, 2017,19(7):471-473
- 391 [21] Lin Y. Journal of Clinical Ultrasound in Medicine[D]. Guangxi Medical University, 2014.
- 392 [22] Jia W R. Study on contrast-enhanced ultrasound based on different molecular subtypes of bre 393 ast cancer[D]. Shanghai Jiao Tong University, 2015.
- Wang B T. The application value of serum tumor markers combined with dynamic detection in the diagnosis and monitoring of breast cancer[D]. Qingdao University, 2021.
- [24] Ghadge M S, Naik P P, Tiwari B P, et al. A Comparative Study of Bone Scan Findings and
 Serum Levels of Tumor Marker CA15-3 in Patients with Breast Carcinoma[J]. Indian J Clin
 Biochem, 2012,27(1):97-99.DOI: 10.1007/s12291-011-0168-5
- 399 [25] Wang G, Qin Y, Zhang J, et al. Nipple discharge of CA15-3, CA125, CEA and TSGF as a 400 new biomarker panel for breast cancer[J]. Int J Mol Sci, 2014,15(6):9546-9565.DOI: 10.3390 401 /ijms15069546















